AOA Dx · Jun 2026
AOA Dx reported 92% sensitivity for early-stage ovarian cancer detection in symptomatic women at ASCO 2026, alongside 96.5% sensitivity and 80.6% specificity in symptomatic women.
Blood Test for Early Detection of Ovarian Cancer
Company research
Public company, workplace, funding, and market signals
Overview
AOA Dx is a Denver-based women's health diagnostics biotech founded in 2020 that is developing AI-enabled, multi-omic blood tests for early ovarian cancer detection, centered on its GlycoLocate platform and AKRIVIS GD assay.
Primary product
AKRIVIS GD™
Founded
2020
Headquarters
6860 Broadway, Denver, Colorado 80221, United States
Team size
11-50 employees
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
Women's health diagnostics
Offices
Denver, Colorado, United States
New York City, New York, United States
Boston, Massachusetts, United States
Business model
B2B diagnostic test development
clinical validation and research collaborations
future reimbursed diagnostic commercialization
Funding
Stage
Series B - III
Total raised
$36.7M
Latest round
Series B - III · May 2026
People & investors
Leadership
Chief Executive Officer & Co-Founder
Chief Operating Officer & Co-Founder
Chief Regulatory Officer & Co-Founder
Chief Product Officer
Chief Scientific Officer
Senior Director, Biomarker & Analytical Development
Senior Director, R&D
Director, R&D
Elizabeth Yarber
Senior Director of Clinical Operations
Founders
Chief Regulatory Officer & Co-Founder
Investors
Adaptive Capital Partners
AlleyCorp
Astia Fund
Avestria Ventures
Easton Capital
Elizabeth Elting Foundation
Endless Frontier Labs
FemHealth Ventures
Foreground Capital
Good Growth Capital
Gore Range Capital
Harper Ventures
IKJ Capital
Joyance Partners
Kyto Technology and Life Science
Labcorp Venture Fund
Launchpad Venture Group
LongeVC
Olive Tree Capital
RH Capital
Rhia Ventures
TBD Angels
The Helm
Venture Science
VU Venture Partners
Y Combinator
Work & culture
Mission-driven and innovation-focused, with public hiring language emphasizing problem solvers and a team-oriented effort to transform women's health and early cancer detection.
Work style
Flexible
Compensation
Public job postings show Denver salary bands of $130,000-$160,000 and $160,000-$175,000 for technical roles, with geography-based adjustment; broader bonus, equity, and visa policy are not publicly disclosed.
Benefits
unlimited PTO
group health insurance
dental insurance
vision insurance
100% employee-sponsored life insurance
100% employee-sponsored disability insurance
monthly cell phone reimbursement
401(k) with employer match
Product & market
Pricing
Not publicly disclosed; appears to be a provider-facing diagnostic / reimbursement model.
Differentiators
- —multi-omic liquid biopsy combining lipids, proteins, and other biomarkers
- —machine-learning interpretation of biomarker signatures
- —focus on symptomatic women rather than population screening
- —GlycoLocate platform underpinning AKRIVIS GD
- —publicly reported high early-stage ovarian cancer sensitivity
Technology
AI
machine learning
multi-omics
lipidomics
proteomics
metabolomics
LC-MS
Python
Java
C
Smartsheet
Adobe
Microsoft
LinkedIn
AMP
Customers
healthcare providers
women presenting with vague abdominal or pelvic symptoms
clinical trial sites and research partners
Competitors
Mercy BioAnalytics
Aspira Women's Health
CanSense
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
5.4K
Traffic estimate as of Mar 2026
Latest news
AOA Dx · May 2026
The company enrolled the first participant in a prospective multi-site APEX study in the U.S. and Europe to expand its biobank of symptomatic women.
AOA Dx · Apr 2026
AOA Dx hired Cory Bystrom to advance the platform through clinical validation, CLIA operations, and future FDA submissions.
AOA Dx · Mar 2026
Chris Roberts was appointed Chief Product Officer to lead product strategy, commercialization, and market access for AKRIVIS GD.
AOA Dx · Jan 2026
AOA Dx released its "Follow the Exits" report, estimating more than $100B in realized women’s health exit value across 272 exits between 2000 and 2024.
Jobs and careers at AOA Dx
0 jobs at AOA Dx
No open positions
Check back later for new openings